Novanta Inc. (NOVT) Stock: Price, Forecast & Analyst Target
Novanta Inc. (NOVT) — MoonshotScore 65/100 (Strong band), calculated Oct 5, 2026. Price $150.61 (+0.90%), as of the Oct 5, 2026 trading session; market cap $5.36B. Expected results Nov 2, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 7.46× (market value Oct 5, 2026; cash Jul 3, 2026) · expected results Nov 2, 2026
Novanta Inc. · NOVT · NASDAQ · Technology · Hardware, Equipment & Parts
Research dated 2026-09-13: Novanta manufactures advanced photonics, precision motion, and imaging components for medical and industrial customers. The company is profitable, generates positive cash flow, and has achieved profitable scale, but future growth depends on whether new market penetration and product innovation can offset commodity-like competition in its established segments.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Novanta (NOVT)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, though growth is only middling; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Flat; Momentum: Rising.
- quarterly revenue $266M (Q2 FY2026, quarter ended Jul 2026)
- EPS beat 6 of 8
- Altman Z 7.45 · Piotroski F 7
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 68 | Strong | |
| 65 | Fair | |
| 65 | Fair | |
| 65 | Fair | |
| 65 | Fair | |
| 65 | Fair |
The score moved from 68 in the stored Oct 4, 2026 snapshot to 65 in the current publication computed Oct 5, 2026 (-3); the largest pillar moves were Momentum -7 and Growth Durability +1.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $150.61 | |
| Change on the day | +0.90% | |
| 52-week range | $98.27 – $176.38 | |
| Market capitalisation | $5.36B | |
| Price / earnings (trailing) | 100.00 | |
| Shares traded on the day | 335K | |
| Beta (volatility vs the S&P 500) | 1.68 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
As a consequence, for the full year 2026, we now expect GAAP revenue to be approximately $1,130 billion to $1,140 billion, which not only raises our organic growth outlook, but incorporates the Riverpoint Medical acquisition in our outlook.
Robert Buckley · Statement from
For Novanta's adjusted gross margins, we expect the third quarter to come in at approximately 48%.
Robert Buckley · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Novanta (NOVT): Bullish Lean
60/100 · B+Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the NOVT film — every key number, told as a short cinematic story
~2 min · open the film
What is Novanta (NOVT), and what does it report?
Short answer · as of
Novanta operates in segments serving vastly different markets: Advanced Surgery (medical insufflators, video systems), Precision Medicine (laser diagnostics, measurement), Precision Manufacturing (industrial lasers and laser scanning), and Robotics and Automation (motion control for robots and machinery).
Research dated 2026-09-13.
Novanta operates in segments serving vastly different markets: Advanced Surgery (medical insufflators, video systems), Precision Medicine (laser diagnostics, measurement), Precision Manufacturing (industrial lasers and laser scanning), and Robotics and Automation (motion control for robots and machinery). Revenue is tied to capital equipment sales cycles and recurring maintenance contracts; products are engineered, not commoditized.
Reported revenue reflects a mix of product sales and service revenue. Gross margins vary by segment: high-margin laser products contrast with lower-margin surgical equipment. Operating income shows the company has reached maturity and can fund R&D from operations without diluting shareholders, unlike pure-growth stage competitors.
What do the latest results show for Novanta (NOVT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $266M.
Research dated 2026-09-13.
Recent quarters showed stable revenue and consistent profitability. Earnings have beaten estimates consistently, suggesting the company guides conservatively or has genuine competitive advantages in execution.
The mechanism is that capital equipment cycles are predictable and Novanta's installed base of systems generates recurring revenue through consumables and service contracts. A quarter with better results signals stronger demand from OEM customers; weaker results suggest either capital spending delays or competitive pressure on pricing.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $265.81M Jul 3, 2026
- Latest quarter · R&D
- $23.97M Jul 3, 2026
- Latest quarter · SG&A
- $59.97M Jul 3, 2026
- Latest quarter · FMP standardized operating result
- $18.06M Jul 3, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 3, 2026 | $265.81M | $23.97M | $59.97M | $18.06M |
| Apr 3, 2026 | $257.71M | $23.25M | $54.41M | $30.14M |
| Dec 31, 2025 | $258.35M | $22.87M | $51.58M | $30.69M |
| Sep 26, 2025 | $247.84M | $24.09M | $51.38M | $28.52M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $265.81M Aug 5, 2026
- Latest report · revenue estimate
- $262.30M Aug 5, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 5, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 5, 2026 | $265.81M | $262.30M | $0.8900 | $0.8300 |
| May 11, 2026 | $257.70M | $253.40M | $0.8100 | $0.7800 |
| Feb 23, 2026 | $258.35M | $255.59M | $0.9100 | $0.8800 |
| Nov 3, 2025 | $247.84M | $255.59M | $0.8700 | $0.8100 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $266M | $13M | $0.30 (diluted) |
| Q1 FY2026 | $258M | $21M | $0.51 (diluted) |
| Q4 FY2025 | $258M | $17M | $0.45 (diluted) |
| Q3 FY2025 | $248M | $11M | $0.30 (diluted) |
What are the financial strengths and risks for Novanta (NOVT)?
Short answer
Cash and short-term investments were $718.65M at the Jul 3, 2026 balance-sheet date. Operating cash flow was $66.23M for the quarter ended Jul 3, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Balance sheet is strong: the company holds substantial cash, carries modest debt, and generates positive operating cash flow each quarter. Quick ratio shows the company could fund operations for many months from liquid balances. Interest coverage is healthy.
The central risk is cyclical capital equipment demand. If industrial customers delay laser system purchases or medical device companies reduce capital expenditures, Novanta revenue falls immediately. A second risk is competition: Asian manufacturers can produce simpler laser components at lower cost, creating pressure on margins in commodity segments. Novanta's profitability depends on maintaining pricing power through specialization and brand.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $66.23M Jul 3, 2026
- Previous quarter · operating cash flow
- $50.31M Apr 3, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jul 3, 2026 | $66.23M | −$7.47M |
| Apr 3, 2026 | $50.31M | −$4.14M |
| Dec 31, 2025 | $8.81M | −$3.67M |
| Sep 26, 2025 | $8.49M | −$4.28M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Novanta (NOVT)?
Short answer · as of
The next earnings report is expected on Nov 2, 2026.
Research dated 2026-09-13.
Track bookings and backlog trends. If future order intake remains strong, that suggests underlying market demand is solid. Monitor also for customer commentary about capital spending plans: procurement delays in earnings calls would suggest near-term revenue pressure.
Watch for management commentary on competitive dynamics and pricing. If they discuss price increases sticking in the market, that signals strong demand and differentiation; if they defend current pricing, that suggests competitive intensity. Recent M&A activity (Riverpoint acquisition) warrants monitoring to see if integration adds synergies or absorbs management attention.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
As a consequence, for the full year 2026, we now expect GAAP revenue to be approximately $1,130 billion to $1,140 billion, which not only raises our organic growth outlook, but incorporates the Riverpoint Medical acquisition in our outlook.
Robert Buckley ·
For Novanta's adjusted gross margins, we expect the third quarter to come in at approximately 48%.
Robert Buckley ·
For adjusted EBITDA in the third quarter, we expect it to be seen between $74 million and $77 million, representing 27% to 33% increase year-over-year. And we expect to achieve approximately a 25% EBITDA margin, which is 150 basis points higher than the prior year and quarter.
Robert Buckley ·
Some of these costs were temporarily higher in the second quarter, and we expect gross margins to sequentially expand materially in the third quarter.
John Lesica ·
How does Novanta compare with its peers?
Short answer
Novanta's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Novanta competes with diversified industrial companies like Parker Hannifin and Roper Technologies, as well as specialized laser manufacturers like IPG Photonics and Lumentum. Novanta's advantage is application-specific expertise: its systems are sold to OEM customers who need the precision and reliability, not commodity performance. That specialization justifies premium pricing.
Novanta's market position is defensible because customers invest in Novanta solutions and integrate them into their own products; switching costs are high. However, commoditization risk persists: if manufacturing advances lower the cost of precision manufacturing, customers may eventually opt for lower-cost substitutes.
| Company | Price | Market value | Score |
|---|---|---|---|
| $305.61 Oct 5, 2026 | $13.9B | 80 5-pillar Oct 5, 2026 | |
| $257.63 Oct 5, 2026 | $3.72B | 80 5-pillar Oct 5, 2026 | |
| $124.89 Oct 5, 2026 | $3.60B | 78 5-pillar Oct 5, 2026 | |
| $64.37 Oct 5, 2026 | $10.8B | 77 5-pillar Oct 5, 2026 | |
| $87.79 Oct 5, 2026 | $3.79B | 75 5-pillar Oct 5, 2026 | |
| $159.10 Oct 5, 2026 | $2.86B | 74 5-pillar Oct 5, 2026 | |
| $271.92 Oct 5, 2026 | $7.12B | 71 5-pillar Oct 5, 2026 | |
| $31.89 Oct 5, 2026 | $4.47B | 68 5-pillar Oct 5, 2026 | |
| $86.11 Oct 5, 2026 | $3.14B | 67 5-pillar Oct 5, 2026 | |
| Novanta (NOVT) — this page | $150.61 | $5.36B | 65 |
| $273.18 Oct 5, 2026 | $7.31B | 64 5-pillar Oct 5, 2026 | |
| $43.17 Oct 5, 2026 | $6.34B | 63 5-pillar Oct 5, 2026 | |
| $197.87 Oct 5, 2026 | $3.26B | 63 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $194.00 – $194.00
- Consensus target
- $194.00
- Median target
- $194.00
Consensus record · Captured .
Measured against a quoted price of $150.61 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 11, 2026
- Transactions
- 19
- Identified insiders
- 2
- Purchases
- 0
- Sales
- 19
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 408 Period end Jun 30, 2026
- Previous quarter · holders
- 343 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 4,798,035 |
| Vanguard Portfolio Management LLC | 2,395,681 |
| Price T Rowe Associates INC /Md/ | 2,222,445 |
| Daiwa Securities Group INC. | 2,142,000 |
| Allspring Global Investments Holdings, LLC | 1,817,594 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Novanta (NOVT)?
What Investors Ask About Novanta (NOVT) — Technology
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Is Novanta's growth rate sustainable?
Growth depends on market penetration, new product adoption, and favorable capital spending cycles. Recent guidance suggests steady expansion, but the company does not guide for acceleration. Maintenance of current growth requires that R&D investments yield products customers value enough to pay premium pricing.
What is the risk of commoditization?
Simpler laser systems and motion control products face commodity pressure from lower-cost manufacturers. Novanta's premium segments (medical imaging, robotic guidance) show stronger defensibility. If industrial customers migrate away from high-spec systems to lower-cost alternatives, margins would compress materially.
How much is profitability from recurring versus product sales?
Recurring revenue (maintenance, consumables, service) provides earnings stability; product sales cycles create volatility. A shift toward higher recurring revenue would reduce earnings cyclicality. Current mix gives Novanta resilience but also exposure to capital spending downturns.
Could Novanta be acquisition target or acquirer?
Novanta's profitability and cash generation make it attractive to larger industrial conglomerates seeking specialty tech. Conversely, management has pursued M&A to consolidate fragmented markets. Strategic fit depends on whether an acquirer sees synergies in distribution or R&D; Novanta's modest scale means it could enhance, not transform, a larger buyer.
What is the NOVT stock price today?
The last price recorded on this page for Novanta Inc. (NOVT) is $150.61, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NOVT price target?
The analyst consensus price target for Novanta Inc. (NOVT) is $194.00 (range $194.00 to $194.00, median $194.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Robert Buckley (Aug 6, 2026): As a consequence, for the full year 2026, we now expect GAAP revenue to be approximately $1,130 billion to $1,140 billion, which not only raises our organic growth outlook, but incorporates the Riverpoint Medical acquisition in our outlook. Robert Buckley (Aug 6, 2026): For Novanta's adjusted gross margins, we expect the third quarter to come in at approximately 48%. Robert Buckley (Aug 6, 2026): For adjusted EBITDA in the third quarter, we expect it to be seen between $74 million and $77 million, representing 27% to 33% increase year-over-year. And we expect to achieve approximately a 25% EBITDA margin, which is 150 basis points higher than the prior year and quarter. John Lesica (Aug 6, 2026): Some of these costs were temporarily higher in the second quarter, and we expect gross margins to sequentially expand materially in the third quarter. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 125 Middlesex Turnpike, ., Bedford, MA, 01730 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "125 Middlesex Turnpike, Bedford, MA, 01730, US". |
FMP — 71 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 2, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $150.61 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T20:00:01.000Z. | |
px.change | Change on the day | +0.90% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.36B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:01.000Z. Captured from FMP at 2026-10-05T20:24:52.390Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$1.34 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $266M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 100.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 335K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.68 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Matthijs Glastra | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 3,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $706.79M, net result $50.33M; FY2022 revenue $860.90M, net result $74.05M; FY2023 revenue $881.66M, net result $72.88M; FY2024 revenue $949.25M, net result $64.09M; FY2025 revenue $980.60M, net result $53.83M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Advanced Surgery $242.44M · Precision Medicine $237.32M · Precision Manufacturing $182.26M · Robotics and Automation $318.58M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 42.5% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-07-03.revenue_k | Revenue — period end 2026-07-03 | $265.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-03.rd_k | R&D — period end 2026-07-03 | $23.97M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-03.sga_k | SG&A — period end 2026-07-03 | $59.97M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-07-03.operating_result_k | FMP standardized operating result — period end 2026-07-03 | $18.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-03.revenue_k | Revenue — period end 2026-04-03 | $257.71M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-03.rd_k | R&D — period end 2026-04-03 | $23.25M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-03.sga_k | SG&A — period end 2026-04-03 | $54.41M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-04-03.operating_result_k | FMP standardized operating result — period end 2026-04-03 | $30.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $258.35M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $22.87M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $51.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $30.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-26.revenue_k | Revenue — period end 2025-09-26 | $247.84M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-26.rd_k | R&D — period end 2025-09-26 | $24.09M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-26.sga_k | SG&A — period end 2025-09-26 | $51.38M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-26.operating_result_k | FMP standardized operating result — period end 2025-09-26 | $28.52M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-05.revenue_actual | Revenue · reported — report date 2026-08-05 | $265.81M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.revenue_estimated | Revenue · estimate — report date 2026-08-05 | $262.30M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_actual | EPS · reported — report date 2026-08-05 | $0.8900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_estimated | EPS · estimate — report date 2026-08-05 | $0.8300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.revenue_actual | Revenue · reported — report date 2026-05-11 | $257.70M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.revenue_estimated | Revenue · estimate — report date 2026-05-11 | $253.40M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_actual | EPS · reported — report date 2026-05-11 | $0.8100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-11.eps_estimated | EPS · estimate — report date 2026-05-11 | $0.7800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_actual | Revenue · reported — report date 2026-02-23 | $258.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_estimated | Revenue · estimate — report date 2026-02-23 | $255.59M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_actual | EPS · reported — report date 2026-02-23 | $0.9100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_estimated | EPS · estimate — report date 2026-02-23 | $0.8800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_actual | Revenue · reported — report date 2025-11-03 | $247.84M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_estimated | Revenue · estimate — report date 2025-11-03 | $255.59M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_actual | EPS · reported — report date 2025-11-03 | $0.8700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_estimated | EPS · estimate — report date 2025-11-03 | $0.8100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $718.65M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $66.23M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-07-03. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $282.82M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.79× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-07-03.operating_cash_flow_m | Operating cash flow — period end 2026-07-03 | $66.23M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-03.operating_cash_flow_m | Operating cash flow — period end 2026-04-03 | $50.31M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-07-03.capex_m | Capital expenditure (reported) — period end 2026-07-03 | −$7.47M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-04-03.capex_m | Capital expenditure (reported) — period end 2026-04-03 | −$4.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $8.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$3.67M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-26.operating_cash_flow_m | Operating cash flow — period end 2025-09-26 | $8.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-26.capex_m | Capital expenditure (reported) — period end 2025-09-26 | −$4.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $194.00 – $194.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $194.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $194.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 19 transactions · 0 purchases, 19 sales, 0 other transactions · 2 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 11, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 408 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 343 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 4,798,035 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 2,395,681 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 2,222,445 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Daiwa Securities Group INC. — shares in provider snapshot | 2,142,000 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Allspring Global Investments Holdings, LLC — shares in provider snapshot | 1,817,594 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-12 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 7.45 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
px.range52 | 52-week range | $98.27 – $176.38 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 7.46× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $718.65M at Jul 3, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-07-03. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-05.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($265.81M) with the recorded estimate ($262.30M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-05.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.8900) with the recorded estimate ($0.8300) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 65 of 100 · Strong · pillars 56 / 83 / 37 / 46 / 75 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 68 (stored snapshot Oct 4, 2026) → 65 (current publication computed Oct 5, 2026) (-3) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-07-03. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-07-03.revenue_k,fin.q_table.depth.2026-07-03.rd_k,fin.q_table.depth.2026-07-03.sga_k,fin.q_table.depth.2026-07-03.operating_result_k,fin.q_table.depth.2026-04-03.revenue_k,fin.q_table.depth.2026-04-03.rd_k,fin.q_table.depth.2026-04-03.sga_k,fin.q_table.depth.2026-04-03.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-26.revenue_k,fin.q_table.depth.2025-09-26.rd_k,fin.q_table.depth.2025-09-26.sga_k,fin.q_table.depth.2025-09-26.operating_result_k. - Earnings-history note. Source series as of 2026-08-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-05.revenue_actual,earn.history.depth.2026-08-05.revenue_estimated,earn.history.depth.2026-08-05.revenue_actual.comparison,earn.history.depth.2026-08-05.eps_actual.comparison,earn.history.depth.2026-08-05.eps_actual,earn.history.depth.2026-08-05.eps_estimated,earn.history.depth.2026-05-11.revenue_actual,earn.history.depth.2026-05-11.revenue_estimated,earn.history.depth.2026-05-11.eps_actual,earn.history.depth.2026-05-11.eps_estimated,earn.history.depth.2026-02-23.revenue_actual,earn.history.depth.2026-02-23.revenue_estimated,earn.history.depth.2026-02-23.eps_actual,earn.history.depth.2026-02-23.eps_estimated,earn.history.depth.2025-11-03.revenue_actual,earn.history.depth.2025-11-03.revenue_estimated,earn.history.depth.2025-11-03.eps_actual,earn.history.depth.2025-11-03.eps_estimated. - Cash-flow note. Source series as of 2026-07-03. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-07-03.operating_cash_flow_m,fin.opcf.depth.2026-04-03.operating_cash_flow_m,fin.opcf.depth.2026-07-03.capex_m,fin.opcf.depth.2026-04-03.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-26.operating_cash_flow_m,fin.opcf.depth.2025-09-26.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplied to Original Equipment Manufacturers (OEMs) across the medical and industrial sectors. Within its Photonics division, Novanta provides a suite of laser-driven technologies. These encompass systems for laser scanning, beam manipulation, and various laser types such as CO2, solid-state, ultrafast, and optical light engines. Their applications span critical areas like industrial manufacturing, precision measurement (metrology), advanced imaging in healthcare and biological research, DNA sequencing, and specialized medical laser treatments. The Vision segment delivers an array of medical-grade innovations. This portfolio comprises instruments like medical insufflators, pumps, and their associated consumables, alongside comprehensive visualization tools. It also features wireless communication systems, video recording devices, and integration platforms designed for operating theaters. Further offerings include optical data acquisition, machine vision systems, radio frequency identification (RFID) solutions, thermal recording devices, spectrometry equipment, and integrated touchscreen displays. Furthermore, the Precision Motion division specializes in supplying components such as optical and inductive encoders, high-precision motors, servo drives, and complete motion control systems. This segment also delivers integrated stepper motors, sophisticated robotic end-effectors, air bearings, and air bearing spindles. Novanta distributes its extensive product lines through various channels, including its dedicated direct sales team, value-added resellers, distribution partners, and system integrators. These offerings are available under well-known brand names such as Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind. Founded in 1968, the company operated as GSI Group, Inc. until its rebranding to Novanta Inc. in May 2016. Its corporate headquarters are located in Bedford, Massachusetts. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-07-03 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Revenue by segment | Advanced Surgery: $242.44M; Precision Medicine: $237.32M; Precision Manufacturing: $182.26M; Robotics and Automation: $318.58M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-05 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash, investments and debt | Total debt: $282.82M; Liquidity basis: cash and short-term investments; Total liabilities: $523.11M; Cash and short-term investments: $718.65M; Cash and investments: $718.70M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-07-03 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Trailing twelve-month ratio set | Quick ratio: 3.79; Current ratio: 4.57; Debt to equity: 0.17; Net margin: 6%; Gross margin: 42.5%; Operating margin: 10.4%; Return on assets: 2.9%; Return on equity: 4.9% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-07-03 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Next earnings report | Date: 2026-11-02; EPS estimate: $0.97 per share; Revenue estimate: $301.02M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-06 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Insider transactions, last 180 days | Net shares: -33,500; Window days: 180; Price low: $130.05; Price high: $171.28; Buy transactions: 0; Distinct insiders: 1; Sell transactions: 18; Other transactions: 0; Total transactions: 18; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-07-02 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
At most 2 analysts contributed — treat this as thin coverage, not a consensus. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Institutional ownership (13F) | Holders: 406; Quarter: 2026-06-30; Holders previous quarter: 343 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Analyst actions, most recent per firm | Captured record · 3 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-05-13 | FMP | Financial Modeling Prep (FMP) analyst grades |
Data provided for informational purposes only.